Skip to main content
P

Prestige BioPharma Limited — Investor Relations & Filings

Ticker · 950210 ISIN · KR8702070002 KO Manufacturing
Open in API
Filings indexed 188 across all filing types
Latest filing 2026-03-13 Regulatory Filings
Country SG Singapore
Listing KO 950210

About Prestige BioPharma Limited

https://prestigebiopharma.com/

Prestige BioPharma Limited is a biopharmaceutical company specializing in the discovery, development, and commercialization of antibody-based therapeutics. The company's portfolio is centered on two primary areas: the development of high-quality biosimilars and the creation of innovative, first-in-class antibody drugs. Its operations encompass the full drug development lifecycle, including preclinical and clinical research, alongside Chemistry, Manufacturing, and Controls (CMC) activities. Prestige BioPharma maintains a diverse pipeline of drug candidates in various stages of development, focusing on advancing biopharmaceutical technologies to provide novel therapeutic solutions for patients.

Recent filings

Filing Released Lang Actions
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It details amendments to contract terms such as the end date and payment conditions for a pharmaceutical supply agreement with Teva. Since this is a specific regulatory disclosure of a material business contract amendment and does not fit into categories like M&A, financial reports, or board changes, it is classified as a general Regulatory Filing (RNS).
2026-03-13 Korean
반기보고서 (2025.12)
Interim / Quarterly Report Classification · 1% confidence The document is titled '반기보고서' (Semi-annual Report) for Prestige Biopharma, covering the period from July 1, 2025, to December 31, 2025. It contains detailed financial data, business operations, management discussions, and capital structure information. As it is a comprehensive financial report for a period shorter than a full fiscal year (a semi-annual report) and includes substantive financial statements and analysis, it is classified as an Interim/Quarterly Report. H2 2025
2026-03-03 Korean
[기재정정]단일판매ㆍ공급계약체결
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Correction Report' (정정신고) for a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It details changes to contract terms such as the end date and payment conditions for a pharmaceutical supply agreement with Teva. Since this is a specific regulatory disclosure of a material business event (contract amendment) and does not fit into categories like M&A, dividends, or financial reports, it is classified as a general Regulatory Filing (RNS).
2026-01-29 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled '임시주주총회 결과' (Extraordinary General Meeting Results) and details the outcome of a shareholder vote, specifically the appointment of an outside director and audit committee member. This falls directly under the definition of 'Declaration of Voting Results & Voting Rights Announcements'.
2026-01-21 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment, dismissal, or resignation of an outside director (사외이사). This type of corporate governance disclosure specifically pertains to changes in the board of directors, which falls under the 'Board/Management Information' category.
2026-01-21 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal 'Notice of Extraordinary General Meeting' (주주총회소집공고) for Prestige Biopharma. It details the meeting date, location, agenda items (specifically the appointment of an outside director who will serve on the audit committee), and provides background information on the candidate and the company's business status for shareholders. This document is a standard proxy statement/notice for a shareholder meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2026-01-06 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.